Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-08-18), Protalix BioTherapeutics's 12-1 Month Momentum % is 54.55%.
The industry rank for Protalix BioTherapeutics's 12-1 Month Momentum % or its related term are showing as below:
PLX's 12-1 Month Momentum % is ranked better than 83.06% of 1358
companies
in the Biotechnology industry
Industry Median: -20.005
vs PLX: 54.55
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Protalix BioTherapeutics 12-1 Month Momentum % Related Terms
PLX vs GLSI, DTIL, NERV: 12-1 Month Momentum % Comparison
For the Biotechnology subindustry, Protalix BioTherapeutics's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Protalix BioTherapeutics 12-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Protalix BioTherapeutics's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Protalix BioTherapeutics's 12-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Protalix BioTherapeutics (PLX) has a 12-1 Month Momentum % of 54.55% as of Aug. 18, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Protalix BioTherapeutics and its competitors. According to the industry distribution chart, Protalix BioTherapeutics ranks #230 out of 1358 companies in the Biotechnology industry, placing it in the top 16.9%.
Is Protalix BioTherapeutics' 12-1 Month Momentum % too high?
Protalix BioTherapeutics' current 12-1 Month Momentum % is 54.55%. Based on the distribution chart, Protalix BioTherapeutics ranks #230 out of 1358 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Protalix BioTherapeutics has a GF Score™ of 54/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Protalix BioTherapeutics' 12-1 Month Momentum % compare to GLSI and DTIL?
According to the Biotechnology industry distribution chart, Protalix BioTherapeutics ranks #230 out of 1358 companies for 12-1 Month Momentum %. This places Protalix BioTherapeutics in the top 17% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Biotechnology company?
A good 12-1 Month Momentum % depends on the Biotechnology industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Protalix BioTherapeutics and its competitors. Protalix BioTherapeutics's current 12-1 Month Momentum % is 54.55%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Protalix BioTherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Protalix BioTherapeutics (PLX) is currently considered Fairly Valued. The stock's GF Value™ is $2.20, compared to a current price of $2.34 — trading 6.4% above its estimated fair value. The current 12-1 Month Momentum % is 54.55%. Protalix BioTherapeutics' overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For Protalix BioTherapeutics (PLX), the current 12-1 Month Momentum % is 54.55% as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Protalix BioTherapeutics (PLX) Overvalued in 2026?
Based on GuruFocus' analysis, Protalix BioTherapeutics stock appears to be overvalued.
The current stock price of $2.34 is trading 6.4% above its estimated GF Value™ of $2.20.
GuruFocus considers Protalix BioTherapeutics to be Fairly Valued.
Key valuation signals for PLX:
12-1 Month Momentum %: 54.55%
GF Value™: $2.20 vs. price of $2.34 (6.4% above fair value)
No single metric tells the full story. See the PLX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
54GF Score
Get the complete analysis for PLX
12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PLX has been successfully added to your 
